← Back to Search

Tyrosine Kinase Inhibitor

Selective Tyrosine Kinase Inhibitor for Solid Tumors

Phase 1
Recruiting
Research Sponsored by Qurient Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with histologically or cytologically confirmed advanced or metastatic solid tumors, that have progressed following standard of care therapy or for which there is no standard therapy which confers clinical benefit
ECOG performance status 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 2 years
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and has any anti-cancer activity.

Who is the study for?
This trial is for adults with advanced or metastatic solid tumors that have worsened after standard treatments, or when no effective standard treatment exists. Participants must be able to perform daily activities with ease or only slight limitations and should expect to live at least another 3 months.Check my eligibility
What is being tested?
The study is testing Q702, an oral medication aimed at certain cancer-related enzymes. It's in Phase 1 where researchers are figuring out the best dose by gradually increasing it among small groups of patients while monitoring safety and how well the drug works against tumors.See study design
What are the potential side effects?
While specific side effects for Q702 aren't listed, common ones for drugs targeting tyrosine kinases include diarrhea, skin issues, high blood pressure, fatigue, nausea, and liver function changes. Side effects can vary widely from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has spread and worsened after standard treatment or lacks a beneficial standard treatment.
Select...
I am fully active or can carry out light work.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702
Secondary outcome measures
Change in the area under curve (AUC) of Q702
Change in the maximum plasma concentration (Cmax) of Q702
Change in the time of maximum plasma concentration (Tmax) of Q702
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose escalation (Q702)Experimental Treatment1 Intervention
Participants will receive escalating doses of Q702

Find a Location

Who is running the clinical trial?

Qurient Co., Ltd.Lead Sponsor
8 Previous Clinical Trials
729 Total Patients Enrolled

Media Library

Q702 (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04648254 — Phase 1
Solid Tumors Research Study Groups: Dose escalation (Q702)
Solid Tumors Clinical Trial 2023: Q702 Highlights & Side Effects. Trial Name: NCT04648254 — Phase 1
Q702 (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04648254 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor open to participants at the moment?

"As per the clinicaltrials.gov listing, this study is actively recruiting participants. Its first post was on November 18th 2020 and its latest update took place on September 1st 2022."

Answered by AI

To what extent is the sample size of this experiment?

"This clinical trial requires 78 qualified individuals to join. Those who meet the prescribed criteria can participate from University of Southern California in Chicago, Illinois and Northwestern University in Morristown, New jersey, amongst other sites."

Answered by AI

What safety protocols have been observed with Q702?

"Due to the limited available data on Q702's efficacy and safety, our team at Power gave this a score of 1."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
2020. "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04648254.
~13 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top